Novavax files submission to UK regulator for Covid-19 vaccine approval after Blackpool trial

The firm behind the vaccine said it anticipates a “positive decision” following the completion of its rolling regulatory submission to the Medicines and Healthcare products Regulatory Agency (MHRA).

More than 15,000 people took part in the phase 3 Novavax trial at various hospital sites across the UK, including Blackpool.

Novavax said its application for conditional marketing authorisation (CMA) marks the first submission for authorisation of a protein-based coronavirus vaccine in the UK.

Britain has ordered 60 million doses of the vaccine.

Novavax boss Stanley Erck thanked all trial participants.

It is thanks to our loyal readers that we can continue to provide the trusted news, analysis and insight that matters to you. For unlimited access to our unrivalled local reporting, you can take out a subscription here and help support the work of our dedicated team of reporters.